Which has preferable valuation and earnings, CBLL or WRBY?

Warby Parker has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.77 -$53.41M -$1.63 N/A Warby Parker $871.91M 2.79 $1.64M $0.02 1,134.35

Is CBLL or WRBY more profitable?

Warby Parker has a net margin of 0.15% compared to CeriBell's net margin of -63.51%. Warby Parker's return on equity of 2.30% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Warby Parker 0.15% 2.30% 1.18%

Does the media refer more to CBLL or WRBY?

In the previous week, CeriBell and CeriBell both had 1 articles in the media. Warby Parker's average media sentiment score of 1.79 beat CeriBell's score of 0.00 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Warby Parker 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer TMDX or CBLL?

In the previous week, TransMedics Group had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for TransMedics Group and 1 mentions for CeriBell. TransMedics Group's average media sentiment score of 0.28 beat CeriBell's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LMAT or CBLL?

In the previous week, LeMaitre Vascular had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for LeMaitre Vascular and 1 mentions for CeriBell. LeMaitre Vascular's average media sentiment score of 0.10 beat CeriBell's score of 0.00 indicating that LeMaitre Vascular is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LeMaitre Vascular 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, AXGN or CBLL?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $225.21M 10.11 -$15.70M -$0.64 N/A CeriBell $89.06M 7.77 -$53.41M -$1.63 N/A

Is AXGN or CBLL more profitable?

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.21% -9.63% -6.26% CeriBell -63.51% -38.19% -30.92%

Does the media prefer AXGN or CBLL?

In the previous week, AxoGen had 1 more articles in the media than CeriBell. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for CeriBell. AxoGen's average media sentiment score of 1.67 beat CeriBell's score of 0.00 indicating that AxoGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CBLL or ESTA?

In the previous week, CeriBell and CeriBell both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.11 beat CeriBell's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Establishment Labs 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CeriBell (CBLL) Competitors

$18.25 -0.50 (-2.67%)

Closing price 04:00 PM Eastern

Extended Trading

$18.24 0.00 (-0.03%)

As of 04:15 PM Eastern

Compare

CBLL vs. WRBY, TMDX, LMAT, AXGN, and ESTA

Should you buy CeriBell stock or one of its competitors? MarketBeat compares CeriBell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CeriBell include Warby Parker (WRBY), TransMedics Group (TMDX), LeMaitre Vascular (LMAT), AxoGen (AXGN), and Establishment Labs (ESTA). These companies are all part of the "medical equipment" industry.

How does CeriBell compare to Warby Parker?

CeriBell (NASDAQ:CBLL) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

CeriBell has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.96, indicating that its share price is 96% more volatile than the broader market.

Warby Parker has a net margin of 0.15% compared to CeriBell's net margin of -63.51%. Warby Parker's return on equity of 2.30% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Warby Parker	0.15%	2.30%	1.18%

93.2% of Warby Parker shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Warby Parker has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A
Warby Parker	$871.91M	2.79	$1.64M	$0.02	1,134.35

In the previous week, CeriBell and CeriBell both had 1 articles in the media. Warby Parker's average media sentiment score of 1.79 beat CeriBell's score of 0.00 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CeriBell currently has a consensus target price of $22.20, suggesting a potential upside of 21.64%. Warby Parker has a consensus target price of $29.50, suggesting a potential upside of 30.03%. Given Warby Parker's higher probable upside, analysts plainly believe Warby Parker is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Warby Parker beats CeriBell on 12 of the 16 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	3.96	$190.29M	$4.40	15.78
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to CeriBell's net margin of -63.51%. TransMedics Group's return on equity of 22.38% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
CeriBell	-63.51%	-38.19%	-30.92%

TransMedics Group presently has a consensus target price of $134.00, indicating a potential upside of 93.00%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 21.64%. Given TransMedics Group's higher probable upside, equities analysts clearly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

TransMedics Group has a beta of 1.91, meaning that its share price is 91% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

In the previous week, TransMedics Group had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for TransMedics Group and 1 mentions for CeriBell. TransMedics Group's average media sentiment score of 0.28 beat CeriBell's score of 0.00 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

TransMedics Group beats CeriBell on 13 of the 17 factors compared between the two stocks.

How does CeriBell compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, LeMaitre Vascular had 2 more articles in the media than CeriBell. MarketBeat recorded 3 mentions for LeMaitre Vascular and 1 mentions for CeriBell. LeMaitre Vascular's average media sentiment score of 0.10 beat CeriBell's score of 0.00 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.65	$57.73M	$2.71	34.86
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A

LeMaitre Vascular has a net margin of 24.35% compared to CeriBell's net margin of -63.51%. LeMaitre Vascular's return on equity of 15.36% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
CeriBell	-63.51%	-38.19%	-30.92%

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Comparatively, 20.1% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

LeMaitre Vascular currently has a consensus price target of $112.60, suggesting a potential upside of 19.18%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 21.64%. Given CeriBell's stronger consensus rating and higher probable upside, analysts clearly believe CeriBell is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

LeMaitre Vascular beats CeriBell on 11 of the 15 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

AxoGen (NASDAQ:AXGN) and CeriBell (NASDAQ:CBLL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

80.3% of AxoGen shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 20.1% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 8.64%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 21.64%. Given CeriBell's stronger consensus rating and higher possible upside, analysts plainly believe CeriBell is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$225.21M	10.11	-$15.70M	-$0.64	N/A
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A

In the previous week, AxoGen had 1 more articles in the media than CeriBell. MarketBeat recorded 2 mentions for AxoGen and 1 mentions for CeriBell. AxoGen's average media sentiment score of 1.67 beat CeriBell's score of 0.00 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has a net margin of -13.21% compared to CeriBell's net margin of -63.51%. AxoGen's return on equity of -9.63% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
CeriBell	-63.51%	-38.19%	-30.92%

AxoGen has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

AxoGen beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to Establishment Labs?

CeriBell (NASDAQ:CBLL) and Establishment Labs (NASDAQ:ESTA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

CeriBell currently has a consensus target price of $22.20, indicating a potential upside of 21.64%. Establishment Labs has a consensus target price of $87.14, indicating a potential upside of 17.27%. Given CeriBell's stronger consensus rating and higher possible upside, equities analysts clearly believe CeriBell is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Establishment Labs has higher revenue and earnings than CeriBell. Establishment Labs is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.77	-$53.41M	-$1.63	N/A
Establishment Labs	$211.08M	10.36	-$51.06M	-$1.49	N/A

CeriBell has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Establishment Labs has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, CeriBell and CeriBell both had 1 articles in the media. Establishment Labs' average media sentiment score of 1.11 beat CeriBell's score of 0.00 indicating that Establishment Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Establishment Labs	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

72.9% of Establishment Labs shares are owned by institutional investors. 20.1% of CeriBell shares are owned by company insiders. Comparatively, 10.0% of Establishment Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Establishment Labs has a net margin of -19.05% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Establishment Labs	-19.05%	-218.77%	-12.31%

Summary

Establishment Labs beats CeriBell on 10 of the 16 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$711.43M	$8.48B	$6.49B	$12.46B
Dividend Yield	N/A	2.52%	2.67%	5.34%
P/E Ratio	-11.20	16.14	23.93	23.64
Price / Sales	7.77	6.93	517.32	112.53
Price / Cash	N/A	17.32	42.35	57.17
Price / Book	4.36	3.56	9.73	6.37
Net Income	-$53.41M	$224.05M	$3.56B	$337.36M
7 Day Performance	-1.14%	-1.56%	-3.19%	-3.07%
1 Month Performance	-10.41%	1.59%	-0.11%	0.37%
1 Year Performance	4.29%	-1.05%	25.29%	27.87%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	1.6617 of 5 stars	$18.25 -2.7%	$22.20 +21.6%	+9.4%	$711.43M	$89.06M	N/A	N/A
WRBY Warby Parker	4.4266 of 5 stars	$25.13 +2.9%	$29.50 +17.4%	+18.4%	$2.61B	$890.57M	1,215.16	4,036	Positive News
TMDX TransMedics Group	4.5188 of 5 stars	$69.71 +3.2%	$134.00 +92.2%	-45.0%	$2.33B	$635.89M	15.07	210
LMAT LeMaitre Vascular	4.6878 of 5 stars	$91.07 -0.4%	$112.60 +23.6%	+12.8%	$2.16B	$249.60M	33.40	490	Analyst Forecast
AXGN AxoGen	2.5493 of 5 stars	$39.66 +2.4%	$46.50 +17.2%	+288.9%	$2.10B	$238.11M	N/A	450	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. WRBY, TMDX, LMAT, AXGN, and ESTA

How does CeriBell compare to Warby Parker?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to LeMaitre Vascular?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to Establishment Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. WRBY, TMDX, LMAT, AXGN, and ESTA

How does CeriBell compare to Warby Parker?

Which has more volatility & risk, CBLL or WRBY?

Is CBLL or WRBY more profitable?

Do insiders & institutionals have more ownership in CBLL or WRBY?

Which has preferable valuation and earnings, CBLL or WRBY?

Does the media refer more to CBLL or WRBY?

Do analysts rate CBLL or WRBY?

Summary

How does CeriBell compare to TransMedics Group?

Which has better valuation & earnings, TMDX or CBLL?

Do institutionals & insiders believe in TMDX or CBLL?

Is TMDX or CBLL more profitable?

Do analysts prefer TMDX or CBLL?

Which has more volatility & risk, TMDX or CBLL?

Does the media prefer TMDX or CBLL?

Summary

How does CeriBell compare to LeMaitre Vascular?

Does the media prefer LMAT or CBLL?

Which has preferable valuation & earnings, LMAT or CBLL?

Is LMAT or CBLL more profitable?

Do institutionals and insiders hold more shares of LMAT or CBLL?

Which has more volatility and risk, LMAT or CBLL?

Do analysts prefer LMAT or CBLL?

Summary

How does CeriBell compare to AxoGen?

Do insiders and institutionals believe in AXGN or CBLL?

Do analysts recommend AXGN or CBLL?

Which has higher valuation & earnings, AXGN or CBLL?

Does the media prefer AXGN or CBLL?

Is AXGN or CBLL more profitable?

Which has more risk and volatility, AXGN or CBLL?

Summary

How does CeriBell compare to Establishment Labs?

Do analysts recommend CBLL or ESTA?

Which has higher earnings & valuation, CBLL or ESTA?

Which has more volatility & risk, CBLL or ESTA?

Does the media refer more to CBLL or ESTA?

Do institutionals and insiders believe in CBLL or ESTA?

Is CBLL or ESTA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools